

1 Systematic Review

2 **Review and methodological analysis of trials currently testing treatment and prevention**  
3 **options for COVID-19 globally.**

4 Paraskevi C. Fragkou<sup>1,2,§,\*</sup>, Drifa Belhadi<sup>3,4,§</sup>, Charalampos D. Moschopoulos<sup>1,¥</sup>, Nathan  
5 Peiffer-Smadja<sup>3,5,¥</sup>, François-Xavier Lescure<sup>3,5</sup>, Hannah Janocha<sup>6</sup>, Emmanouil Karofylakis<sup>1</sup>,  
6 Yazdan Yazdanpanah<sup>3,5</sup>, France Mentré<sup>3,4</sup>, Chrysanthi Skevaki<sup>2,6</sup>, Cédric Laouénan<sup>3,4,#</sup>,  
7 Sotirios Tsiodras<sup>1,2,#</sup> on behalf of the ESCMID Study Group for Respiratory Viruses.

8 <sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, Medical School, National and Kapodistrian University  
9 of Athens, Attikon University Hospital, Athens, Greece

10 <sup>2</sup> European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group  
11 for Respiratory Viruses (ESGREV)

12 <sup>3</sup> Université de Paris, IAME, INSERM, F-75018 Paris, France

13 <sup>4</sup> Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat –  
14 Claude-Bernard, AP-HP, 75018 Paris, France

15 <sup>5</sup> Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique  
16 Hôpitaux de Paris, Paris, France

17 <sup>6</sup> Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre  
18 (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg,  
19 Germany

20 \***Corresponding author:** Paraskevi C. Fragkou, 4<sup>th</sup> Department of Internal Medicine,  
21 Medical School, National and Kapodistrian University of Athens, Attikon University  
22 Hospital, Chaidari, Athens, 12462, Greece. Tel: +306973388299, Fax: +30 2105326446,  
23 Email: [evita.fragou@gmail.com](mailto:evita.fragou@gmail.com).

24   <sup>§</sup> Equal contribution as first authors

25   <sup>¥</sup> Equal contribution as second authors

26   <sup>#</sup> Equal contribution as senior authors

27   **Abstract word count:** 294 words

28   **Main manuscript word count:** 3873 words

29

30 **ABSTRACT**

31 **Background:** As COVID-19 cases continue to rise globally within an unprecedented short  
32 period of time, solid evidence from large randomised controlled trials is still lacking.  
33 Currently, numerous trials testing potential treatment and preventative options are undertaken  
34 globally.

35 **Objectives:** We summarised all currently registered clinical trials examining treatment and  
36 prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved  
37 interventional studies.

38 **Data sources:** Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union  
39 Clinical Trials Register were systematically searched.

40 **Study eligibility criteria:** Registered clinical trials examining treatment and/or prevention  
41 options for COVID-19 were included. No language, country or study design restrictions were  
42 applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or  
43 preventative strategies for COVID-19.

44 **Participants and interventions:** No restrictions in terms of participants' age and medical  
45 background or type of intervention were enforced.

46 **Methods:** The registries were searched using the term "coronavirus" or "COVID-19" from  
47 their inception until 26<sup>th</sup> March 2020. Additional manual search of the registries was also  
48 performed. Eligible studies were summarised and tabulated. Interventional trials were  
49 methodologically analysed, excluding expanded access studies and trials testing Traditional  
50 Chinese Medicine.

51 **Results:** In total, 309 trials evaluating therapeutic management options, 23 studies assessing  
52 preventive strategies and 3 studies examining both were retrieved. Interventional treatment  
53 studies were mostly randomised (n=150, 76%) and open-label (n=73, 37%) with a median

54 number of planned inclusions of 90 (IQR 40-200).Major categories of interventions that are  
55 currently being investigated are discussed.

56 **Conclusion:** Numerous clinical trials have been registered since the onset of the COVID-19  
57 pandemic. Summarised data on these trials will assist physicians and researchers to promote  
58 patient care and guide future research efforts for COVID-19 pandemic containment.  
59 However, up to the end of March, 2020, significant information on reported trials was often  
60 lacking.

61

62 **Keywords:** SARS-CoV-2; COVID-19; novel coronavirus; pneumonia; treatment; prevention;  
63 antivirals; immunomodulators; anti-inflammatory; clinical trials.

64

## 65 INTRODUCTION

66 COVID-19 pandemic induced by the Severe Acute Respiratory Syndrome coronavirus 2  
67 (SARS-CoV-2) has already affected most countries globally [1]. As of April 12, 2020, more  
68 than 1,690,000 COVID-19 cases have been officially reported leading to more than 150,900  
69 deaths worldwide, with numbers constantly rising on a daily basis as the virus continues to  
70 spread exponentially [2,3].

71 The original source of SARS-CoV-2 is still debatable, though phylogenetic data analysis  
72 converge into the hypothesis that SARS-CoV-2 has possibly originated from bat SARS-like  
73 coronaviruses (CoVs) [4–6]. Human CoVs are positive-sense single-stranded RNA (+ssRNA)  
74 viruses belonging to the *Orthocoronavirinae* subfamily [7]. The analysis of viral genome as  
75 well as structural and non-structural proteins plays central role in identifying candidate  
76 treatment targets [7]. Notably, the SARS-CoV-2 surface spike glycoprotein (S-protein) is a  
77 key structural component that controls the viral interaction with hosts' angiotensin I  
78 converting enzyme 2 (ACE2) receptor in order to invade human epithelial cells [8].  
79 Moreover, molecules directed against non-structural proteins such as the viral protease or  
80 pathways imperative for viral genome replication, alone or along with boosters or regulators  
81 of the host's immune system, constitute promising therapeutic strategies[8,9].

82 Given the steep upsurge of COVID-19 cases worldwide within an unprecedented short period  
83 of time, we are still waiting for solid evidence from large randomised controlled trials  
84 regarding targeted antiviral treatments. In this systematic review, we aim firstly to summarise  
85 the data on all currently tested treatment and prevention options for the COVID-19 disease,  
86 and secondly to methodologically analyse and evaluate the quality of the registered  
87 interventional studies.

88

## 89 METHODS

90 Registered clinical trials were systematically searched at the ClinicalTrials.gov database[10],  
91 the Chinese Clinical Trial Registry[11] and the European Union Clinical Trials Register [12]  
92 from their inception up to 26<sup>th</sup> March 2020 using the search terms “coronavirus” or “COVID-  
93 19”. Additional manual search of the registries was performed for possibly unidentified  
94 studies. No language, country or study design restrictions were applied. Participants of any  
95 age and medical background with or at risk for COVID-19 were included, as were any  
96 currently tested intervention related to the treatment or prevention of COVID-19.

97 We excluded withdrawn or cancelled studies and trials not reporting therapeutic or  
98 preventative measures for COVID-19. Eligible studies were summarised and tabulated.

99 Methodological analysis of the interventional studies was performed. Traditional Chinese  
100 Medicine (TCM) and homeopathy were excluded from the in-depth qualitative assessment, as  
101 we have no expertise to analyse clinical trials testing these agents that rely on controversial  
102 scientific rationale [13,14]. We evaluated the study design, number of planned inclusions and  
103 primary outcomes of interventional studies, excluding retrospective and “expanded access”  
104 studies. Studies were also analysed according to their primary endpoint, i.e. clinical,  
105 virological (viral excretion in clinical samples), radiological (imaging results such as CT-scan  
106 or X-rays), or biological / immunological (complete blood count, CR, CD8+/CD4+ T cells  
107 count, etc.). This review was conducted according to the PRISMA guidelines [15].

108

## 109 **RESULTS**

### 110 **1. General data retrieved**

111 In total, 335 studies were retrieved, including 309 trials evaluating therapeutic molecules,  
112 devices and other management options, 23 studies assessing medications, vaccines under  
113 development and other preventive strategies, and 3 studies examining both (Figure 1, Table

114 S1, Table S2). An overview of currently tested therapeutic interventions is presented in Figure  
115 2 and Figure 3.

116

## 117 **2. Main treatment interventions**

118

### 119 **Protease Inhibitors**

120 Lopinavir is a protease inhibitor (PI) active against human immunodeficiency virus 1 (HIV-1)  
121 infection. The main coronavirus proteinase (3C-like proteinase or 3CL<sup>pro</sup>) plays a key role in  
122 processing viral polyproteins [16,17]. PIs effectively inhibit the 3CL<sup>pro</sup> enzyme, thus posing a  
123 possibly potent therapeutic agent against SARS-CoV-2 infection.

124 PIs have shown effectiveness against SARS-CoV, MERS-CoV and SARS-CoV-2 viruses in  
125 *in vitro* susceptibility models [18–21]. During SARS-CoV epidemic, lopinavir boosted by  
126 ritonavir (a cytochrome P450-3A4 inhibitor) with or without ribavirin, significantly reduced  
127 adverse outcomes including mortality[22]. The MIRACLE trial that examines the efficacy of  
128 ritonavir boosted lopinavir combined with recombinant interferon-beta 1b (IFN-β1b) in the  
129 treatment of MERS, is currently undertaken in Saudi Arabia and results are pending [23].

130 For COVID-19, lopinavir/ritonavir combined with or without other agents has been reported  
131 to successfully reduce adverse outcomes in sporadic cases from China [24–27]. These  
132 promising reports have set the ground for numerous trials addressing the safety and efficacy  
133 of PIs in SARS-CoV-2 infection (Table 1). Other PIs that are currently being assessed are  
134 ritonavir boosted ASC09 (a novel PI), cobicistat boosted darunavir as well as the NS3/4A  
135 protease inhibitor danoprevir combined with ritonavir (Table 1, Table S1).

136

### 137 **RNA polymerase inhibitors**

138 SARS-CoV-2 and SARS-CoV RNA-dependent RNA polymerase (RdRp) share 96%  
139 sequence identity; this has justified the assumption that inhibitors effective against SARS-  
140 CoV could have similar inhibitory effects against SARS-CoV-2[28]. Nucleoside analogues  
141 compete with natural nucleosides for the RdRp active site, thus inhibiting the viral genome  
142 replication [29].Current research efforts focus on repurposing older moleculesinCOVID-19  
143 treatment, as their safety profile has already been documented [30].

144 Remdesivir (GS-5734<sup>TM</sup>) is an adenosine analogue with broad-spectrum antiviral properties  
145 [31]. Preclinical data demonstrated the efficacy of remdesivir against SARS-CoV and MERS-  
146 CoV, as it has the potential to outcompete the proofreading ability of coronavirus  
147 exonuclease, and carries a high genetic resistance barrier [21,28,30,32]. Wang et al.  
148 confirmed its *in vitro* efficacy against SARS-CoV-2 [33].Currently, it is investigated in 7  
149 randomised, controlled trials (Table 1, Table S1).

150 Favipiravir is a nucleoside analogue inhibiting the RNA polymerase, initially approved for the  
151 treatment of novel influenza viruses [34]. It is also effective against a broad range of viruses,  
152 including positive-sense single-stranded RNA viruses [34]. Since there have been some  
153 promising *in vitro* results for its efficacy against SARS-CoV-2, favipiravir is now being  
154 investigated in 8 clinical trials.

155 Ribavirin is a guanosine analogue that inhibits inosine monophosphate dehydrogenase  
156 required for the synthesis of guanosine triphosphate, leading to lethal mutagenesis of RNA  
157 genome [35]. Ribavirin was used in SARS epidemic in combination with either  
158 lopinavir/ritonavir or interferon alpha (IFN- $\alpha$ ), and these combinations are currently  
159 recommended by the China National Practice Guidelines for the treatment of severe COVID-  
160 19 [22,36].

161 Azvudine, an azidocytidine analogue that inhibits viral reverse transcriptase,has been  
162 effective against HIV, hepatitis B and C viruses [37]. Its efficacy against SARS-CoV-2 is



163 being tested in 3 ongoing clinical trials (Table 1, Table S1). Another nucleoside analogue  
164 undergoing investigation for COVID-19 pneumonia is emtricitabine/tenofovir alafenamide.

165

#### 166 **Anti-malaria drugs**

167 Chloroquine and hydroxychloroquine are currently licensed for the treatment of malaria and  
168 autoimmune diseases [38]. However, they have also been studied against several viruses with  
169 promising *in vitro* results, never confirmed in humans [39–41]. As weak bases, they are  
170 concentrated in acidic intra-cellular organelles, leading to alkalization and distraction of the  
171 low pH-dependent steps of viral replication, including viral-cell fusion and uncoating [38,40].  
172 Moreover, they impair the terminal glycosylation of ACE2 receptor in Golgi apparatus, thus  
173 inhibiting the viral penetration into the host cells [42].

174 As they are accumulated in lymphocytes and macrophages, these drugs reduce secretion of  
175 proinflammatory cytokines, and particularly of tumour necrosis factor alpha (TNF- $\alpha$ ) [41].  
176 Experimental data demonstrated that chloroquine is highly effective *in vitro* against SARS-  
177 CoV-2 in an estimated effective concentration that is easily achievable with standard dosing  
178 regimens [33]. Preliminary results from small studies suggested the effectiveness of  
179 chloroquine, alone or combined with azithromycin, in viral clearance, inhibition of  
180 pneumonia exacerbation, improvement of lung imaging and shortening of the disease course  
181 [43,44]. However, clinical trials with a control group are needed to provide reliable answers  
182 for clinicians.

183

#### 184 **Immunomodulators and anti-inflammatory drugs**

185 Virus-induced exuberant immune response leading to cytokine storm syndrome (CSS) and  
186 secondary haemophagocytic lymphohistiocytosis (HLH) is probably the underlying

187 pathogenetic mechanism that leads to critical and often fatal COVID-19 infection [45,46].  
188 Hyperinflammation is associated with acute respiratory distress syndrome (ARDS) and  
189 fulminant multi-organ failure that is fatal if left untreated. In this context, immunosuppressors  
190 (along with antivirals) may play a key role in counteracting severe SARS-CoV-2 infection  
191 [45].

192 Preliminary data from COVID-19 patients in China reported significantly higher interleukin  
193 (IL)-6 levels in patients with critical COVID-19 disease than those with severe or mild  
194 disease [47]. Tocilizumab and sarilumab, both humanised monoclonal antibodies (mAbs)  
195 against the IL-6 receptor, are currently evaluated in 14 clinical trials (Table 1, Table S1);  
196 tocilizumab, in particular, improved symptoms and laboratory parameters in a small  
197 retrospective study in China [48]. Various other molecules oriented against different  
198 cytokines, as well as intra- and extra-cellular inflammatory pathways, are currently being  
199 tested in COVID-19 including: adalimumab, anti-programmed cell death protein 1 mAbs,  
200 bevacizumab, ixekizumab, eculizumab, human recombinant IL-2, inhibitors of NLRP3  
201 inflammasome activation (trnilast), Janus Kinase inhibitors, fingolimod and a recombinant  
202 fusion protein targeting an immune pathway checkpoint (CD24Fc). Clinical trials on other  
203 immunotherapies (i.e. gimsilumab, siltuximab, lenzilumab and leronlimab) have been  
204 proposed, but have not been registered yet.

205 Immunomodulators licensed for haematological and rheumatological conditions (such as  
206 leflunomide and thalidomide), as well as colchicine that counteracts the assembly of the  
207 NLRP3 inflammasome, are also being studied for their therapeutic use against SARS-CoV-2  
208 (Table 1, Table S1) [49].

209 The immunomodulatory effects of macrolide antibiotics, as well as their pharmacodynamic  
210 property to achieve at least 10-fold higher concentrations in epithelial lung fluid than in  
211 serum, have led researchers to repurpose them against SARS-CoV-2 (Table 1, Table S1)

212 [50,51]. Preliminary results of a study have shown significant viral load reduction in patients  
213 treated with hydroxychloroquine plus azithromycin [43].

214 Corticosteroids are major anti-inflammatory drugs, with a conflicting safety profile in severe  
215 viral infections [52]. However, their use is currently recommended by the European Society of  
216 Intensive Care Medicine in COVID-19 cases with shock and/or evidence of CSS/HLH and/or  
217 mechanically ventilated patients with ARDS [53]. Corticosteroids are being tested in 11  
218 clinical trials (Table 1, Table S1).

219 Finally, immunostimulatory molecules that enhance the hosts' immune response against the  
220 invading pathogen, like IFN- $\alpha$ , interferon beta (IFN- $\beta$ ), the recombinant protein produced by  
221 DNA-shuffling of IFN- $\alpha$  (novaferon), the inactivated *Mycobacterium* vaccine and thymosin  
222  $\alpha 1$ , are evaluated as viable therapeutic options in various combinations against SARS-CoV-2  
223 [54].

224

## 225 **Membrane fusion inhibitors and inhibitors of ACE2 receptor connection**

226 SARS-CoV-2 S-protein binds ACE2 receptor on the epithelial cells' membrane [55]. The  
227 host's type II transmembrane serine protease (TMPRSS2) facilitates membrane fusion and  
228 augments viral internalization by cleaving and activating the S-protein [56,57]. These  
229 proteins, being an integral part of the viral life cycle, can be used as possible therapeutic  
230 targets.

231 ACE inhibitors (ACEi) selectively inhibit ACE1 but not ACE2, as they are structurally  
232 different enzymes [58]. Experimental animal models show that angiotensin II type 1 receptor  
233 blockers (ARBs) and ACEi may up-regulate ACE2 expression; although this raised concerns  
234 that ACEi and ARBs may be associated with a more severe form of COVID-19, there is no  
235 evidence supporting that ACE2 up-regulation augments the virulence or the penetration of the

236 virus into the hosts' cells as of yet [58,59]. Contrarily, renin-angiotensin system (RAS)  
237 inhibition may ameliorate the over-accumulation of angiotensin II induced by the down-  
238 regulation of ACE2 noted in other CoVs infection, thus possibly protecting against the  
239 development of fulminant myocarditis and ARDS [58]. In spite of controversial data, 2  
240 randomised controlled trialstesting losartan are currently undertaken in the USA.

241 Camostat mesilate is a potent serine protease inhibitor, inhibiting the TMPRSS2 and is  
242 approved for chronic pancreatitis [60]. *In vitro* experiments have shown that camostat is  
243 effective against SARS-CoV-2[61]. Nafamostat, another inhibitor of TMPRSS2 has been  
244 suggested in COVID-19 therapy, but no registered trials are available yet.

245 Umifenovir is a small indole derivative with a broad-spectrum antiviral activity developed  
246 about 30 years ago [62,63]. Although it is currently used in Russia and China to combat  
247 influenza, it has shown *in vitro* activity against numerous DNA and RNA viruses including  
248 SARS-CoV [62,64,65]. It primarily targets the interaction between viral capsid and the  
249 membrane of the host cell by inhibiting the attachment, the fusion and the internalization of  
250 the virus [62]. Moreover, umifenovir has direct virucidal effects against enveloped viruses  
251 through interaction with the viral lipid envelope or with key residues within structural  
252 proteins of virions [62,65,66]. Limited data support that umifenovir may exhibit  
253 immunomodulatory effects by stimulating hosts' humoral immune response, interferon  
254 production, and phagocytes' activation [67]. A small retrospective study in China  
255 demonstrated some promising results regarding its effectiveness against SARS-CoV-2 when  
256 used in combination with lopinavir/ritonavir [68]. Currently 11 relevant clinical trials are in  
257 progress globally (Table 1, Table S1).

258

259 **Passive immunization**

260 The use of convalescent plasma (CP) to passively immunise patients against viral pathogens  
261 has been previously reported, especially when no other treatment options were available [69].  
262 CP obtained from recovering patients was used during the SARS epidemic; two retrospective  
263 studies demonstrated that CP administration in SARS patients reduced duration of  
264 hospitalisation and mortality rates, when treatment with ribavirin and corticosteroids failed  
265 [70–72].

266 A meta-analysis of patients with severe respiratory infection induced by various viruses  
267 showed a statistically significant reduction of 75% in mortality odds in those who received  
268 CP across all viral aetiologies, including the influenza A 2009 pandemic strain (H1N1pdm09)  
269 and SARS-CoV [73]. Evidence of survival benefit was noted after early administration, while  
270 no serious adverse effects were reported. Although results are pending from 10 relevant  
271 clinical trials, the potential short-lasting immunity after CoV infection has raised  
272 uncertainty regarding the clinical efficacy of CP antibodies in clinical practice [74,75].

273

#### 274 **Cell therapies**

275 Mesenchymal stromal cells (MSCs) exhibit immunomodulating qualities, may skew immune  
276 cell differentiation and have shown promise in H5N1-associated acute lung injury in  
277 preclinical models [76]. A pilot study involving MSC transplantation in 7 patients with  
278 COVID-19 resulted in cure or significant improvement of pulmonary function and symptoms  
279 without adverse effects [77]. MSCs may partially accumulate in lungs and improve the  
280 pulmonary microenvironment. A significant induction of regulatory dendritic cells (DCs),  
281 along with a shift from Th1 towards Th2 immune responses, was also observed [77]. Other  
282 clinical trials utilizing MSCs for curing COVID-19 are ongoing (Table 1, Table S1).

283 MSC-derived exosomes are extracellular bodies mediating intercellular communication,  
284 containing mRNAs, miRNAs, lipids, growth factors and cytokines, that possibly exert the

285 paracrine immunoregulatory effects of MSC [78]. Furthermore, MSC-exosomes'  
286 administration is associated with lower risks (e.g.tumour formation, immunogenicity)  
287 compared to the intravenous injection of MSCs [79].

288 Natural killer cells have shown promising results as adoptive immunotherapy in various  
289 cancers, and may also be potent effector cells in the SARS-CoV-2 infection. A phase 1  
290 clinical trial has been launched to determine their efficacy (Table S1). Lastly, ozone therapy  
291 may inactivate viruses, among other pathogens, and activate the immune system via up-  
292 regulation of Th1 cytokines including IFN and TNF; as such,3 trials have been launched to  
293 evaluate ozone autohaemotherapy efficacy in COVID-19 [80].

294

### 295 **3. Main preventative measures**

296 The World Health Organization (WHO) and the European Centre for Disease Prevention and  
297 Control (ECDC) emphasise the role of screening, precaution measures, exposure prevention  
298 and environmental disinfection as the mainstay of COVID-19 prevention[81,82]. As no  
299 effective preventative options are available yet, several clinical trials are under way to explore  
300 the efficacy of various prevention strategies (Table 2, Table S2).

301 Many studies are currently evaluating the efficacy of TCM in COVID-19 prevention in  
302 China. Importantly, at least 4 vaccines are under development. Among them, an mRNA-based  
303 vaccine encoding the S-protein is being assessed for its safety, reactogenicity and efficacy  
304 against SARS-CoV-2 (Table 2, Table S2). Besides the registered trials, other large companies  
305 have also announced the initiation of vaccine development [83,84].

306 Other preventative molecules include hydroxychloroquine and the recombinant human  
307 interferon  $\alpha$ 1b spray. In the USA, exposed individuals are randomised to hydroxychloroquine  
308 or placebo, evaluating the agent'spotential as post-exposure prophylaxis (NCT04308668,

309 Table S2). Furthermore, another randomised clinical trial evaluates the efficacy of a 3-month  
310 course of chloroquine in at-risk healthcare personnel (NCT04303507, Table S2). Finally, the  
311 live attenuated strain of *Mycobacterium bovis* is expected to be tested as a preventative  
312 strategy against COVID-19 among healthcare professionals, in Australia and France.

313

#### 314 **4. Methodological analysis of interventional studies**

##### 315 **Study Populations**

316 In total, 198 interventional treatment and 16prevention trials were included in the  
317 methodological analysis respectively (Table 3). Among the eligible treatment studies,  
318 children recruitment (i.e.< 14 years old) was reported in 7 clinical trials in total: 1 testing  
319 darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion  
320 (ChiCTR2000029606, ChiCTR2000030944); 1 testing hydroxychloroquine (EudraCT  
321 Number: 2020-000890-25); 1 using tocilizumab (NCT04317092); and 1 assessing nutritional  
322 supplements (NCT04323345) (Table S1).With respect to relevant prevention studies, children  
323 were included in 2 vaccine trials(NCT04276896and NCT04299724) as shown in Table S2.

324

##### 325 **Study designs**

326 Phase IV and phase III treatment trials were the most commonly reported interventional study  
327 types (n=40, 20% and n=35, 18% respectively) as demonstrated in Table 3. Nonetheless, the  
328 majority of registered trials do not disclose the study phase (n=83, 42%).

329 In terms of blinding, 73 open-label (37%), 31 double-blinded (16%), and 16 single-blinded  
330 (8%) studies were retrieved. Most trials were randomised (n=150, 76%) with a parallel

331 assignment between arms. The median (IQR) number of planned inclusions is 90 (40-200)  
332 with a range of 5 to 6000 participants.

333 Phase III and phase I prevention studies were the most commonly reported ones (n=6, 38%  
334 and n=3, 19% respectively, Table3). As with treatment trials, many prevention trials do not  
335 report the study phase (n=4, 25%).

336 Regarding prevention studies' blinding, 6double-blinded (38%), 5open-label (31%), and 2  
337 single-blinded (13%) were found. Most studies were randomised (n=10, 63%) with a parallel  
338 assignment design. The median (IQR) number of planned inclusions is 513 (177-2958)  
339 ranging from 45 to 7576 participants.

340

#### 341 **Treatments and interventions**

342 Various types of interventions are currently evaluated; however, their appraisal is limited by  
343 the lack of reported data concerning the treatment dose and duration. Figure 4 demonstrates  
344 the number of trials by the median of planned inclusions per trial for the ten most frequently  
345 encountered therapies. Although remdesivir is tested in only 7 trials, these studies have the  
346 highest median number of planned inclusions per trial (453, IQR 397-650). On the other hand,  
347 cell therapies are assessed by the highest number of trials (n=25), but with a  
348 disproportionately low median number of planned inclusions (30, IQR 20-60). Figure 5 shows  
349 the total number of planned inclusions and the number of clinical trials for the ten most  
350 frequently studied treatments, with hydroxychloroquine being the treatment associated with  
351 the highest total number (10,146 planned iclusions).

352

#### 353 **Primary endpoints and outcomes**



354 A clinical primary outcome was defined in 128 therapeutic trials (65%; Table 3); most of  
355 them focused on the symptoms' evolution such as time to clinical recovery, the proportion of  
356 patients with clinical improvement or deterioration, length of hospitalisation or mortality. A  
357 number of scores are utilized as primary outcomes such as the ordinal 7-point scale adapted  
358 from the WHO master protocol, the lung injury score, the pneumonia severity index or the  
359 National Early Warning Score 2 score [85–87]. Most prevention studies disclose a clinical  
360 primary outcome (13 studies, 81%), while virological, radiological and  
361 biological/immunological primary endpoints were reported in 39 (20%), 19 (10%), and 12  
362 (6%) studies respectively (Table 3).

363

## 364 **DISCUSSION**

365 The SARS-CoV-2 is the third emerging coronavirus of the last 20 years, but the one that has  
366 led to an evolving pandemic, a fact that urgently requires the implementation of novel  
367 therapeutics. However, repurposing of existing drugs is a viable and less time-consuming  
368 alternative; licensed broad-spectrum antiviral agents with a well-documented safety profile  
369 are currently tested against SARS-CoV-2. Alternatively, screening of chemical compounds'  
370 libraries may be useful in the discovery of an efficacious treatment against COVID-19 disease  
371 [8]. In this review, we have summarised and methodologically appraised the ongoing  
372 therapeutic and preventive trials for COVID-19.

373 Therapeutic strategies should follow the two-phased immune response to COVID-19.  
374 Initially, treatment should aim at strengthening the host's immune response against the virus,  
375 and inhibiting the viral replication [88]. Early initiation of antiviral therapy has been proved  
376 beneficial for the prognosis of patients[89]. As advanced age correlates with higher viral  
377 loads, older patients could strongly benefit from the prompt initiation of antivirals[90].  
378 Moreover, high inflammatory cytokine levels have been correlated with disease severity and

379 the extent of lung damage[91]. Thus, in the later phase of the infection, patients could be  
380 availed by anti-inflammatory therapeutic approaches such as the Janus kinase inhibitors,  
381 blood purification or tocilizumab [92,93].

382 The Chinese National Health Commission recommends antiviral therapy with the protease  
383 inhibitors lopinavir/ritonavir. Other recommended antiviral agents include interferon alpha  
384 and chloroquine phosphate [93]. Advantages of chloroquine include its long clinical history,  
385 known side effects and low cost, which render it a good candidate for global use[33]. The  
386 broad-spectrum antiviral agent remdesivir has successfully been used in individual COVID-  
387 19 cases by the Washington Department of Health[94]. Effectiveness of both chloroquine and  
388 remdesivir against COVID-19 remains to be seen in ongoing trials.

389 Prevention is a key player in combating pandemics. The mRNA 1273 vaccine, is currently in  
390 phase I, but is not expected to be commercially available this year[95]. The prophylactic  
391 potential of hydroxychloroquine/chloroquine is also actively being examined among  
392 healthcare professionals[96]. Moreover, prompt testing and isolation are of utmost importance  
393 for disease prevention. At the moment, real-time quantitative polymerase chain reaction is the  
394 reference standard in diagnostics [97]. The FDA has recently announced the authorisation of  
395 rapid molecular tests that are capable of delivering results within minutes, thus facilitating  
396 early treatment initiation(when viral loads are highest) and timely isolation[90,98,99].

397 Based on the retrieved data, cell therapies and hydroxychloroquine were the most frequently  
398 evaluated candidate therapies (25 and 22 trials respectively), while remdesivir was associated  
399 with the highest median number of planned inclusions per trial (453, IQR 397-650).Although  
400 TCMs and homeopathy represent a large proportion of the identified interventional studies,  
401 we excluded them from our methodological analysis as we do not have the expertise to  
402 analyse clinical trials testing these agents.

403 This review shows the considerable amount of clinical trials that are currently registered.  
404 Although the number of identified trials was high, there were several methodological caveats.  
405 Firstly, study design data and details on the interventions being assessed were often lacking.  
406 This hampers the available information to researchers and relevant stakeholders, and  
407 potentially influences the discovery of successful treatments.

408 Secondly, most trials, and especially those registered at the beginning of the pandemic,  
409 disclosed low participant numbers, which may impact the robustness of their future results.  
410 However, these numbers should be cautiously interpreted, as they represent the anticipated,  
411 and not the actual number of inclusions. Thirdly, reported primary endpoints were highly  
412 heterogeneous among studies. In our opinion, the application of clinical primary endpoints  
413 should be encouraged in an infection where the association between the clinical status and  
414 viral clearance, radiological or immunological evolution is obscure.

415 The identification of the best therapeutic approach is challenging, especially in the context of  
416 a pandemic with thousands of casualties. Our study underlines the need to meticulously  
417 register as many study details as possible on international registries during outbreaks, in order  
418 to guide the development and enhance the consistency of future trials. The development of  
419 clinical trials during an outbreak is an adaptive process and new evidence emerges at an  
420 impressive rate. A review of the early registered clinical trials is an important asset for  
421 researchers and methodologists. These results might encourage transparency when developing  
422 and registering future clinical trials and help improve their methodology, hence the robustness  
423 of their results.

424 In the absence of reliable vaccines and therapies, disease containment plays a pivotal role, as  
425 has been recently observed in China. Undertaking actions such as nationwide temperature  
426 measurements, health recommendations, detection and strict isolation proved to slow down  
427 the transmission rate [100]. The time thereby won is precious for the development of  
428 therapies and vaccines. This approach is especially useful for countries with weaker health

429 systems that lack sufficient medical supplies and infrastructure, and often depend on the  
430 support of the international community.

431

#### 432 **Transparency declaration**

433 *Conflict of interest:* For YY: Chair of the Global Research Collaboration for Infectious  
434 Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTion targeting  
435 emerging infectious diseases (REACTing).

436 For CS: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific;  
437 Consultancy, BencardAllergie; Research Funding, Mead Johnson Nutrition (MJN). Supported  
438 by Universities Giessen and Marburg Lung Centre (UGMLC), the German Centre for Lung  
439 Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding  
440 according to article 2, section 3 cooperation agreement, and the Deutsche  
441 Forschungsgemeinschaft (DFG)-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317/1-1  
442 (Project number 428518790). All grants are outside the submitted work.

443 *Funding:* No external funding was received for this study.

444 *Author contributions:* Conception and design: PCF, ST, DB, NPS, FM, CL. Acquisition of  
445 data: PCF, EK, CDM, HJ, CS, DB, NPS, YY. Interpretation of data: all authors. Drafting the  
446 article: PCF, EK, CDM, HJ, CS, DB, NPS, FM, CL, YY. Revising critically the manuscript  
447 for important intellectual content: PCF, CS, ST. PCF and DB contributed equally as first  
448 authors, CDM and NPS contributed equally as second authors, CL and ST contributed equally  
449 as senior authors. All authors approved the final version of the manuscript submitted.

450

#### 451 **REFERENCES**

- 452 [1] Interim Guidance: Healthcare Professionals 2019-nCoV | CDC n.d.  
453 <https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html> (accessed  
454 April 2, 2020).
- 455 [2] Situation reports n.d. [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)  
456 [2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) (accessed April 2, 2020).
- 457 [3] Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the  
458 EU/EEA and the UK – seventh update. n.d.
- 459 [4] Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G,  
460 Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV)  
461 rejects the hypothesis of emergence as a result of a recent recombination event. *Infect*  
462 *Genet Evol* 2020;79:104212. <https://doi.org/10.1016/j.meegid.2020.104212>.
- 463 [5] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and  
464 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor  
465 binding. *Lancet* 2020;395:565–74. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).
- 466 [6] Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-  
467 new coronavirus epidemic: Evidence for virus evolution. *J Med Virol* 2020;92:455–9.  
468 <https://doi.org/10.1002/jmv.25688>.
- 469 [7] Harrison C. Coronavirus puts drug repurposing on the fast track. *Nat Biotechnol* 2020.  
470 <https://doi.org/10.1038/d41587-020-00003-1>.
- 471 [8] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci*  
472 *Trends* 2020;14:69–71. <https://doi.org/10.5582/bst.2020.01020>.
- 473 [9] Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic  
474 review. *J Med Virol* 2020;92:479–90. <https://doi.org/10.1002/jmv.25707>.
- 475 [10] Home - ClinicalTrials.gov n.d. <https://clinicaltrials.gov/> (accessed April 2, 2020).

- 476 [11] Chinese Clinical Trial Register (ChiCTR) - The world health organization  
477 international clinical trials registered organization registered platform n.d.  
478 <http://www.chictr.org.cn/searchprojen.aspx> (accessed April 2, 2020).
- 479 [12] EU Clinical Trials Register - Update n.d. <https://www.clinicaltrialsregister.eu/>  
480 (accessed April 2, 2020).
- 481 [13] Hard to swallow. *Nature* 2007;448:105–6. <https://doi.org/10.1038/448106a>.
- 482 [14] Ernst E. Homeopathy, a “helpful placebo” or an unethical intervention? *Trends*  
483 *Pharmacol Sci* 2010;31:1. <https://doi.org/10.1016/j.tips.2009.10.005>.
- 484 [15] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred  
485 reporting items for systematic reviews and meta-analyses: The PRISMA statement.  
486 *PLoS Med* 2009;6. <https://doi.org/10.1371/journal.pmed.1000097>.
- 487 [16] Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al.  $\alpha$ -Ketoamides as Broad-  
488 Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based  
489 Design, Synthesis, and Activity Assessment. *J Med Chem* 2020.  
490 <https://doi.org/10.1021/acs.jmedchem.9b01828>.
- 491 [17] Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis, purification, and  
492 substrate specificity of severe acute respiratory syndrome coronavirus 3C-like  
493 proteinase. *J Biol Chem* 2004;279:1637–42. <https://doi.org/10.1074/jbc.M310875200>.
- 494 [18] Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular  
495 dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro)  
496 inhibitors. *J Theor Biol* 2008;254:861–7. <https://doi.org/10.1016/j.jtbi.2008.07.030>.
- 497 [19] Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro susceptibility of  
498 10 clinical isolates of SARS coronavirus to selected antiviral compounds. *J Clin Virol*  
499 2004;31:69–75. <https://doi.org/10.1016/j.jcv.2004.03.003>.

- 500 [20] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S,  
501 Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four  
502 small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication  
503 in cell culture. *Antimicrob Agents Chemother* 2014;58:4875–84.  
504 <https://doi.org/10.1128/AAC.03011-14>.
- 505 [21] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative  
506 therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon  
507 beta against MERS-CoV. *Nat Commun* 2020;11:222. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-019-13940-6)  
508 [019-13940-6](https://doi.org/10.1038/s41467-019-13940-6).
- 509 [22] Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of  
510 lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.  
511 *Thorax* 2004;59:252–6. <https://doi.org/10.1136/thorax.2003.012658>.
- 512 [23] Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al.  
513 Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-  
514 ritonavir and interferon- $\beta$ 1b (MIRACLE trial): study protocol for a randomized  
515 controlled trial. *Trials* 2018;19:81. <https://doi.org/10.1186/s13063-017-2427-0>.
- 516 [24] Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus  
517 disease-19 (COVID-19): the Zhejiang experience]. *Zhejiang Da Xue Xue Bao Yi Xue*  
518 *Ban* 2020;49:0.
- 519 [25] Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis  
520 and treatment of a case infected with coronavirus disease 2019. *J Med Virol*  
521 2020;92:461–3. <https://doi.org/10.1002/jmv.25711>.
- 522 [26] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient  
523 who caused tertiary transmission of coronavirus disease 2019 in Korea: The  
524 application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia

- 525 monitored by quantitative RT-PCR. *J Korean Med Sci* 2020;35.  
526 <https://doi.org/10.3346/jkms.2020.35.e79>.
- 527 [27] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic  
528 procedure for four cases with 2019 novel coronavirus pneumonia receiving combined  
529 Chinese and Western medicine treatment. *Biosci Trends* 2020;14:64–8.  
530 <https://doi.org/10.5582/bst.2020.01030>.
- 531 [28] Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent  
532 Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by  
533 2019-nCoV. *Chembiochem* 2020;21:730–8. <https://doi.org/10.1002/cbic.202000047>.
- 534 [29] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sci*  
535 2020;248:117477. <https://doi.org/10.1016/j.lfs.2020.117477>.
- 536 [30] Martinez MA. Compounds with therapeutic potential against novel respiratory 2019  
537 coronavirus. *Antimicrob Agents Chemother* 2020:1–18.  
538 <https://doi.org/10.1128/AAC.00399-20>.
- 539 [31] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic  
540 efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*  
541 2016;531:381–5. <https://doi.org/10.1038/nature17180>.
- 542 [32] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.  
543 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the  
544 Viral Polymerase and the Proofreading Exoribonuclease. *MBio* 2018;9.  
545 <https://doi.org/10.1128/mBio.00221-18>.
- 546 [33] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine  
547 effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell*  
548 *Res* 2020;30:269–71. <https://doi.org/10.1038/s41422-020-0282-0>.



- 549 [34] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against  
550 neglected and emerging RNA viruses. *Antiviral Res* 2018;153:85–94.  
551 <https://doi.org/10.1016/j.antiviral.2018.03.003>.
- 552 [35] Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new  
553 trick for an old drug? *CMAJ* 2003;168:1289–92.
- 554 [36] Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological,  
555 Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–  
556 Western Medicine for the Management of 2019 Novel Coronavirus Disease. *Am J*  
557 *Chin Med* 2020:1–26. <https://doi.org/10.1142/s0192415x20500378>.
- 558 [37] Wang R-R, Yang Q-H, Luo R-H, Peng Y-M, Dai S-X, Zhang X-J, et al. Azvudine, a  
559 novel nucleoside reverse transcriptase inhibitor showed good drug combination  
560 features and better inhibition on drug-resistant strains than lamivudine in vitro. *PLoS*  
561 *One* 2014;9:e105617. <https://doi.org/10.1371/journal.pone.0105617>.
- 562 [38] Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue  
563 to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob*  
564 *Agents* 2007;30:297–308. <https://doi.org/10.1016/j.ijantimicag.2007.05.015>.
- 565 [39] Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res* 2020;177.  
566 <https://doi.org/10.1016/j.antiviral.2020.104762>.
- 567 [40] Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-  
568 CoV-2. *Int J Antimicrob Agents* 2020;55:105923.  
569 <https://doi.org/10.1016/j.ijantimicag.2020.105923>.
- 570 [41] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of  
571 chloroquine Effects of chloroquine on viral infections□: an old drug against today ’ s  
572 diseases□? *Lancet* 2003;3:722–7. [https://doi.org/10.1016/S1473-3099\(03\)00806-5](https://doi.org/10.1016/S1473-3099(03)00806-5).

- 573 [42] Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the  
574 antiviral effects of chloroquine. *Lancet Infect Dis* 2006;6:67–9.  
575 [https://doi.org/10.1016/S1473-3099\(06\)70361-9](https://doi.org/10.1016/S1473-3099(06)70361-9).
- 576 [43] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.  
577 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an  
578 open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020:105949.  
579 <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
- 580 [44] Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent  
581 efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci*  
582 *Trends* 2020;14:72–3. <https://doi.org/10.5582/bst.2020.01047>.
- 583 [45] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.  
584 COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*  
585 (London, England) 2020;395:1033–4. [https://doi.org/10.1016/S0140-6736\(20\)30628-](https://doi.org/10.1016/S0140-6736(20)30628-0)  
586 0.
- 587 [46] Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine storm  
588 mechanism induced by Corona Virus Disease 2019 and the corresponding  
589 immunotherapies]. *Zhonghua Shao Shang Za Zhi* 2020;36:E005.  
590 <https://doi.org/10.3760/cma.j.cn501120-20200224-00088>.
- 591 [47] Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of  
592 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za*  
593 *Zhi* 2020;43:203–8. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.013>.
- 594 [48] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe  
595 COVID-19 Patients with Tocilizumab. n.d.
- 596 [49] Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-

- 597 activated inflammation and improve obesity-related metabolic dysregulation. *Med*  
598 *Hypotheses* 2016;92:67–73. <https://doi.org/10.1016/j.mehy.2016.04.039>.
- 599 [50] Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. *Mediators*  
600 *Inflamm* 2012;2012:649570. <https://doi.org/10.1155/2012/649570>.
- 601 [51] Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as  
602 immunomodulatory medications. *Clin Microbiol Rev* 2010;23:590–615.  
603 <https://doi.org/10.1128/CMR.00078-09>.
- 604 [52] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid  
605 treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–5.  
606 [https://doi.org/10.1016/S0140-6736\(20\)30317-2](https://doi.org/10.1016/S0140-6736(20)30317-2).
- 607 [53] Important Announcement of new SSC Guidelines – COVID-19 - ESICM n.d.  
608 <https://www.esicm.org/ssc-covid19-guidelines/> (accessed April 2, 2020).
- 609 [54] Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, C-20-15  
610 DisCoVeRy French Steering Committee. Type 1 interferons as a potential treatment  
611 against COVID-19. *Antiviral Res* 2020:104791.  
612 <https://doi.org/10.1016/j.antiviral.2020.104791>.
- 613 [55] Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in  
614 COVID-19 - CEBM n.d. <https://www.cebm.net/covid-19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/> (accessed April  
615 2, 2020).
- 616
- 617 [56] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-  
618 nCoV. *Biochem Biophys Res Commun* 2020.  
619 <https://doi.org/10.1016/j.bbrc.2020.02.071>.
- 620 [57] Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.

- 621           TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by  
622           TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome  
623           Coronavirus Spike Protein. *J Virol* 2014;88:1293–307.  
624           <https://doi.org/10.1128/jvi.02202-13>.
- 625   [58]   Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the  
626           COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-  
627           Angiotensin System Blockers. *Hypertens (Dallas, Tex 1979)*  
628           2020:HYPERTENSIONAHA12015082.  
629           <https://doi.org/10.1161/HYPERTENSIONAHA.120.15082>.
- 630   [59]   Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association  
631           Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for  
632           Epidemiologic Investigations. *Clin Infect Dis* 2020.  
633           <https://doi.org/10.1093/cid/ciaa329>.
- 634   [60]   Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et al.  
635           Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves  
636           Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with  
637           Pancreatic Enzyme Abnormalities. *Digestion* 2019;99:283–92.  
638           <https://doi.org/10.1159/000492813>.
- 639   [61]   Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The  
640           novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and  
641           the cellular protease TMPRSS2 for entry into target cells. *BioRxiv*  
642           2020:2020.01.31.929042. <https://doi.org/10.1101/2020.01.31.929042>.
- 643   [62]   Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update.  
644           *Antiviral Res* 2014;107:84–94. <https://doi.org/10.1016/j.antiviral.2014.04.006>.
- 645   [63]   Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The

- 646 Antiviral Drug Arbidol Inhibits Zika Virus. *Sci Rep* 2018;8:8989.  
647 <https://doi.org/10.1038/s41598-018-27224-4>.
- 648 [64] Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA,  
649 Shoemaker CJ, et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit  
650 Lassa and Ebola Viruses. *J Virol* 2019;93. <https://doi.org/10.1128/jvi.02185-18>.
- 651 [65] Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of arbidol  
652 against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and  
653 adenovirus in vitro and in vivo. *Arch Virol* 2007;152:1447–55.  
654 <https://doi.org/10.1007/s00705-007-0974-5>.
- 655 [66] Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism,  
656 and excretion of the antiviral drug arbidol in humans. *Antimicrob Agents Chemother*  
657 2013;57:1743–55. <https://doi.org/10.1128/AAC.02282-12>.
- 658 [67] Glushkov RG, Gus'kova TA, Krylova LI, Nikolaeva IS. [Mechanisms of arbidole's  
659 immunomodulating action]. *Vestn Ross Akad Meditsinskikh Nauk* 1999:36–40.
- 660 [68] Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r  
661 versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study. *J*  
662 *Infect* 2020. <https://doi.org/10.1016/j.jinf.2020.03.002>.
- 663 [69] Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al.  
664 Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown,  
665 Sierra Leone. *J Infect* 2017;74:302–9. <https://doi.org/10.1016/j.jinf.2016.11.009>.
- 666 [70] Wong VWS, Dai D, Wu AKL, Sung JY. Treatment of severe acute respiratory  
667 syndrome with convalescent plasma. *Hong Kong Med J* 2003;9:199–201.
- 668 [71] Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of  
669 convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol*

- 670 Infect Dis 2005;24:44–6. <https://doi.org/10.1007/s10096-004-1271-9>.
- 671 [72] Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al. Retrospective  
672 comparison of convalescent plasma with continuing high-dose methylprednisolone  
673 treatment in SARS patients. *Clin Microbiol Infect* 2004;10:676–8.  
674 <https://doi.org/10.1111/j.1469-0691.2004.00956.x>.
- 675 [73] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al.  
676 The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the  
677 treatment of severe acute respiratory infections of viral etiology: a systematic review  
678 and exploratory meta-analysis. *J Infect Dis* 2015;211:80–90.  
679 <https://doi.org/10.1093/infdis/jiu396>.
- 680 [74] Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility  
681 of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi  
682 Arabia. *Emerg Infect Dis* 2016;22:1554–61. <https://doi.org/10.3201/eid2209.151164>.
- 683 [75] Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to  
684 SARS-associated coronavirus after recovery. *N Engl J Med* 2007;357:1162–3.  
685 <https://doi.org/10.1056/NEJMc070348>.
- 686 [76] Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al. Therapeutic  
687 Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating  
688 Influenza A(H5N1) Virus-Associated Acute Lung Injury. *J Infect Dis* 2019;219:186–  
689 96. <https://doi.org/10.1093/infdis/jiy478>.
- 690 [77] Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-  
691 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19  
692 Pneumonia. *Aging Dis* 2020;11:216. <https://doi.org/10.14336/ad.2020.0228>.
- 693 [78] Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. *Int J Mol Sci*

- 694 2014;15:4142–57. <https://doi.org/10.3390/ijms15034142>.
- 695 [79] Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: A new  
696 therapeutic paradigm. *Biomark Res* 2019;7. <https://doi.org/10.1186/s40364-019-0159->  
697 x.
- 698 [80] Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. *Int J Artif Organs* 2004;27:168–75.  
699 <https://doi.org/10.1177/039139880402700303>.
- 700 [81] Infection prevention and control n.d. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control)  
701 [coronavirus-2019/technical-guidance/infection-prevention-and-control](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control) (accessed April  
702 2, 2020).
- 703 [82] COVID-19 n.d. <https://www.ecdc.europa.eu/en/covid-19-pandemic> (accessed April 2,  
704 2020).
- 705 [83] Moderna’s COVID-19 vaccine could reach healthcare workers this fall | FierceBiotech  
706 n.d. [https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-](https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-healthcare-workers-fall)  
707 [healthcare-workers-fall](https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-healthcare-workers-fall) (accessed April 2, 2020).
- 708 [84] Johnson & Johnson identifies lead COVID-19 vaccine candidate n.d.  
709 [https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-](https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-covid-19-vaccine-candidate/)  
710 [covid-19-vaccine-candidate/](https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-covid-19-vaccine-candidate/) (accessed April 2, 2020).
- 711 [85] WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis.  
712 2020.
- 713 [86] Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult  
714 respiratory distress syndrome. *Am Rev Respir Dis* 1988;138:720–3.  
715 <https://doi.org/10.1164/ajrccm/138.3.720>.
- 716 [87] Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A  
717 prediction rule to identify low-risk patients with community-acquired pneumonia. *N*

- 718 Engl J Med 1997;336:243–50. <https://doi.org/10.1056/NEJM199701233360402>.
- 719 [88] Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the  
720 perspectives on immune responses. *Cell Death Differ* 2020;1–4.  
721 <https://doi.org/10.1038/s41418-020-0530-3>.
- 722 [89] Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes  
723 to alleviate the severity and improve the prognosis of patients with novel coronavirus  
724 disease (COVID-19). *J Intern Med* 2020. <https://doi.org/10.1111/joim.13063>.
- 725 [90] To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal  
726 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody  
727 responses during infection by SARS-CoV-2: an observational cohort study. *Lancet*  
728 *Infect Dis* 2020;3099:1–10. [https://doi.org/10.1016/S1473-3099\(20\)30196-1](https://doi.org/10.1016/S1473-3099(20)30196-1).
- 729 [91] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
730 infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.  
731 [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 732 [92] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19:  
733 combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis* 2020;20:400–  
734 2. [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8).
- 735 [93] Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) n.d.  
736 [http://en.nhc.gov.cn/2020-03/29/c\\_78469.htm](http://en.nhc.gov.cn/2020-03/29/c_78469.htm) (accessed April 2, 2020).
- 737 [94] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case  
738 of 2019 novel coronavirus in the United States. *N Engl J Med* 2020;382:929–36.  
739 <https://doi.org/10.1056/NEJMoa2001191>.
- 740 [95] NIH clinical trial of investigational vaccine for COVID-19 begins | National Institutes  
741 of Health (NIH) n.d. <https://www.nih.gov/news-events/news-releases/nih-clinical-trial->




- 742           investigational-vaccine-covid-19-begins (accessed April 2, 2020).
- 743   [96]   Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in  
744           the Healthcare Setting - Full Text View - ClinicalTrials.gov n.d.  
745           <https://clinicaltrials.gov/ct2/show/NCT04303507> (accessed April 2, 2020).
- 746   [97]   Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis  
747           of COVID-19. J Pharm Anal 2020. <https://doi.org/10.1016/j.jpha.2020.03.001>.
- 748   [98]   Cepheid | Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use  
749           Authorization n.d. <https://www.cepheid.com/coronavirus> (accessed April 2, 2020).
- 750   [99]   Detect COVID-19 in as Little as 5 Minutes | Abbott Newsroom n.d.  
751           [https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-](https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html)  
752           [little-as-5-minutes.html](https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html) (accessed April 4, 2020).
- 753   [100]  Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)  
754           n.d. [https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))  
755           [on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)) (accessed April 2, 2020).
- 756
- 757

758

759 **Figures:**

760 Figure 1. Systematic review Flow Chart.



761

762

763

764

765

766

767

768

769

770

771


772

773

774

775 Figure 2. Currently tested therapeutic molecules targeting different steps of SARS-CoV-2 life


776 cycle.



777

778 Figure 3. General and supportive therapeutic interventions tested for novel coronavirus disease


779 (COVID-19).



780

781 Figure 4. Number of trials reported by the median of the total number of planned inclusions


782 per trial for the most common treatments.



783

784 Figure 5. Number of trials per total number of planned inclusions for the ten most frequently

785 assessed treatments.



786

787 *Note: The size of the circle corresponds to the addition of the total numbers of planned*

788 *inclusions for all trials evaluating one of the treatments*

789

790 **Tables:**

791 Table 1. Treatment interventions currently being evaluated for the novel coronavirus disease

792 (COVID-19) globally.

<b>Therapeutic Intervention</b>	<b>Countries</b>	<b>No. of trials being tested</b>	<b>No. of RCTs (% of trials per intervention)</b>	<b>Other agents used in combination</b>
TCMs	China	92	61 (66.3)	IFN $\alpha$ , LPV/r, Ribavirin, Chloroquine, Umifenovir, Ulinastatin
Antimalaria drugs (hydroxychloroquine, chloroquine, dihydroartemisinin piperazine)	China, France, Germany, Mexico, Norway, Spain, Brazil, Canada	34	27 (79.4)	Azithromycin, LPV/r, DRV/r or c, Favipiravir, Oseltamivir, Umifenovir, IFN $\alpha$
Lopinavir $\pm$ ritonavir (LPV $\pm$ r)	China, Thailand, Hong Kong, United Kingdom, Europe, South Korea, Canada	32	31 (96.8)	Chloroquine, IFN $\alpha$ , IFN $\beta$ , Navaferon, Thymosin a1, FTC/TAF, Ribavirin, Ebastine, Oseltamivir, Favipiravir, TCM
Cell therapy	China, USA, Brazil, Jordan	30	18 (60)	Ruxolitinib
Interferon (IFN $\alpha$ , IFN $\alpha$ 2 $\beta$ , IFN $\beta$ , rSIFN-co)	China, UK, Hong Kong, Europe	22	22 (100)	Umifenovir, Dihydroartemisinin piperazine, TCM, Bromhexine, Favipiravir, LPV/r, Ribavirin, Ebastine, Danoprevir/r, Thalidomide, Methylprednisolone, TTF2
Anti-IL-6 mAb (Tocilizumab, Sarilumab)	China, Italy, France, Switzerland, Denmark, USA, Canada, Global	14	9 (64.3)	Favipiravir, Adalimumab

Dietary/Supportive	China, Egypt	13	10 (76.9)	N/A
Corticosteroids	China, UK, Italy	11	9 (81.8)	IFN $\alpha$ Umifenovir, Thalidomide
Umifenovir	China	11	11 (100)	Novaferon, IFN $\alpha$ , IFN $\alpha$ 2 $\beta$ , Dihydroartemisinin piperazine, Bromhexine, Favipiravir, Thalidomide, Methylprednisolone
Convalescent plasma	China, Italy	10	7 (70)	N/A
Adjuvant Device	China	9	3 (33.3)	N/A
Favipiravir	China, Thailand	8	8 (100)	Tocilizumab, Bromhexine, IFN $\alpha$ , Umifenovir, (Hydroxy)chloroquine, LPV/r, DRV/r
Remdesivir	Global, Europe, USA, China	8	7 (87.5)	Hydroxychloroquine
Ventilation/ Oxygenation strategies	China	7	0 (0)	N/A
Macrolides (azithromycin, carrimycin)	China, Brazil, Denmark	4	4 (100)	Hydroxychloroquine
Inhaled Gases	China, USA, Italy	4	4 (100)	N/A
JAK inhibitors (Jakotinib, Ruxolitinib, Baricitinib)	China, Italy, Canada	4	2 (50)	Cell therapy, Ritonavir
ACE inhibitor / ARBs	China, USA	3	2 (66.7)	N/A
Azvodine	China	3	1 (33.3)	N/A
Danoprevir/ritonavir	China	3	3 (100)	IFN

Darunavir/cobicistat (DRV/r)	China, Thailand	3	3 (100)	Thymosin a1, Oseltamivir, Hydroxychloroquine, Favipiravir
Pirferidone	China	3	3 (100)	N/A
Anti-PD-1 mAb	China	3	3 (100)	N/A
Oseltamivir	Thailand, China	3	3 (100)	Hydroxychloroquine, DRV/r, LPV/r
Thymosin a1	China	3	3 (100)	DRV/c, LPV/r
Adalimumab	China	2	2 (100)	Tocilizumab
Bevacizumab	China, Italy	2	1 (50)	N/A
Colchicine	Italy, Canada	2	2 (100)	N/A
Novaferon	China	2	2 (100)	LPV/r, Umifenovir
Ribavirin	China, Hong Kong	2	2 (100)	IFN, LPV/r
Thalidomide	China	2	2 (100)	IFN $\alpha$ , Umifenovir, Methylprednisolone
Ulinastatin	China	2	1 (50)	TCM
ASC09/ritonavir	China	2	2 (100)	N/A
Intravenous Immunoglobulin	China	2	2 (100)	N/A
Acetylcysteine	China	1	1 (100)	N/A
Antiviral peptide LL-37	China	1	0 (0)	N/A
Baloxavir Marboxil	China	1	1 (100)	N/A
Bismuth potassium	China	1	1 (100)	N/A
Bronchoscopic alveolar lavage	China	1	0 (0)	N/A



CD24Fc	USA	1	1 (100)	N/A
Dipyridamole	China	1	1 (100)	N/A
Ebastine	China	1	1 (100)	IFN $\alpha$ , LPV/r
Eculizumab	N/A	1	0 (0)	N/A
Enoxaparin	China	1	1 (100)	N/A
Escin	Italy	1	0 (0)	N/A
Fingolimod	China	1	0 (0)	N/A
FTC/TAF	China	1	1 (100)	LPV/r
hrIL-2	China	1	1 (100)	N/A
Inactivated mycobacterial vaccine	China	1	1 (100)	N/A
Itraconazole	Belgium	1	1 (100)	N/A
Ixekizuman	China	1	1 (100)	IFN $\alpha$ , Ribavirin, Chloroquine, LPV/r, Umifenovir
Leflunomide	China	1	1 (100)	N/A
M1	China	1	1 (100)	N/A
Polyinosinic/ polycytidylic acid	China	1	1 (100)	N/A
rhG-CSF	China	1	1 (100)	N/A
Sargramostin (GM-CSF)	Belgium	1	1 (100)	N/A
Sildenafil	China	1	0 (0)	N/A
Siltuximab	Italy	1	0 (0)	N/A
Suramin	China	1	0 (0)	N/A

T89	N/A	1	1 (100)	N/A
TFF-2	China	1	1 (100)	IFN- $\kappa$
TMPRSS2 inhibitor (camostat mesylate)	Denmark	1	1 (100)	N/A
Tranilast	China	1	1 (100)	N/A
VIP	USA, Israel	1	1 (100)	N/A
vMIP	China	1	0 (0)	N/A
Meplazumab (anti- CD147)	China	1	1 (100)	N/A
Sodium Aescinate	China	1	1 (100)	N/A
Triazavirin	China	1	1 (100)	N/A

---

ACE: Angiotensin converting enzyme, Anti-PD-1 mAb: Anti Program Cell Death Protein-1 monoclonal antibody, ARBs: Angiotensin II receptor blockers, CD24Fc: CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, DRV/r or c: Darunavir/ritonavir or cobicistat, FTC/TAF: Emtricitabine/Tenofovir alafenamide, GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor, hrIL-2: human recombinant interleukin 2, IFN $\alpha$ : Interferon alpha, IFN $\beta$ : Interferon beta, INF $\kappa$ : Interferon kappa, IL: Interleukin, JAK: Janus Kinases, LPV/r: Lopinavir/ritonavir, M1: Type I Macrophage, N/A: Not applicable, RCTs: Randomised controlled trials, rhG-CSF: recombinant human Granulocyte-Colony Stimulating Factor, TCMs: Traditional Chinese Medicines, TMPRSS2: Transmembrane Protease Serine 2, TTF-2: Transcription Termination Factor 2, UK: United Kingdom, USA: United States of America, VIP: Vasoactive Intestinal Peptide, vMIP: viral Macrophage Inflammatory Protein.

---

793

794

795 Table 2. Prevention interventions currently being evaluated for the novel coronavirus disease  
 796 (COVID-19) globally.

<b>Prevention intervention</b>	<b>Countries</b>	<b>No. of trials being tested</b>	<b>No. of RCTs (% of trials per intervention)</b>	<b>Other agents used in combination</b>
TCMs	China	10	3 (30)	N/A
Antimalaria Drugs	China, USA, Mexico, UK, Spain	6	6 (100)	Umifenovir, DRV/c
Vaccine	USA, China	4	0 (0)	N/A
Health education	China, Hungary	3	2 (66.7)	TCM
IFN $\alpha$ 1 $\beta$	China	2	0 (0)	Thymosin a1
Darunavir/cobicistat	Spain	1	1 (100)	Chloroquine
Lopinavir/ritonavir	Canada	1	1 (100)	N/A
Mask	Canada	1	1 (100)	N/A
PUL-042	USA	1	1 (100)	N/A
Thymosin a1	China	1	0 (0)	IFN $\alpha$ 1 $\beta$
Umifenovir	China	1	1 (100)	Hydroxychloroquine

DRV/c: Darunavir/cobicistat, IFN $\alpha$ : Interferon alpha, LPV/r: Lopinavir/ritonavir, N/A: Not applicable, RCTs: Randomised controlled trials, TCMs: Traditional Chinese Medicines, UK: United Kingdom, USA: United States of America.

797

798

799 Table 3. Description of the clinical trials registered for the treatment and prevention of  
800 COVID-19.

Study characteristics	Treatment studies	Prevention studies
	N = 198 (%)	N = 16 (%)
Study phase		
Phase I	9 (5)	3 (19)
Phase II*	31 (16)	2 (13)
Phase III**	35 (18)	6 (38)
Phase IV	40 (20)	1 (6)
Unspecified	83 (42)	4 (25)
Study design		
Randomised	150 (76)	10 (63)
Non-randomised	21 (11)	3 (19)
Single-arm	27 (14)	3 (19)
Blinding		
Double-blind	31 (16)	6 (38)
Single-blind	16 (8)	2 (13)
Open-label	73 (37)	5 (31)
Non-applicable†	29 (15)	3 (19)
Unspecified	49 (25)	0 (0)
Total number of planned inclusions		
<50	62 (31)	1 (6)

	50-100	41 (21)	0 (0)
	100-150	32 (16)	3 (19)
	150-200	9 (5)	0 (0)
	200-250	15 (8)	1 (6)
	≥250	39 (20)	11 (69)
Primary endpoint			
	Clinical	128 (65)	13 (81)
	Virological	39 (20)	2 (13)
	Radiological	19 (10)	0 (0)
	Immunological/biological	12 (6)	1 (6)

---

\*Including phase I/II trials; \*\*Including phase II/III trials; †: Single-arm or factorial trials.

---

801